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Intestinal fibrosis is a progressive process characterized by de novo synthesis and 
uncontrolled deposition of extracellular matrix components (ECM) following a tis-
sue chronic inflammation mainly regulated by Transforming Growth Factor (TGF)β/
Smads pathway. Frequently associated to Inflammatory Bowel Disease (IBD), intesti-
nal fibrosis may lead to stenosis and obstructions that require surgery up to 75% of 
patients as drugs currently used in IBD are unable to improve fibrostenosis lesions 
(1). Peroxisome proliferator-activated receptor (PPAR)-γ is able to antagonize (TGF)
β/Smads and could be an crucial target to develop novel antifibrotic therapeutic 
strategies (2). 
Aim of this study is to evaluate the antifibrotic action of a novel PPARγ agonist, 
GED 0507-34 levo, in colonic fibrosis in mice.
Immunohistochemistry and immunoblotting evaluations, TGFβ1, CTGF, Collagen 
types I-III, Smad3, α-SMA, were performed in in three groups of C57BL/6 mice: Dex-
tran Sulphate Sodium (DSS) colitis group, DSS+GED group and controls. 
Evident macroscopic and microscopic lesions in the most of colons of DSS treated 
mice were observed compared to DSS+GED mice and controls. The tissue levels of 
the main markers of fibrosis resulted significantly increased in DSS mice and restored 
by administration of GED.
GED seems to prevents ECM colonic deposition and to improve the intestinal 
fibrotic lesions by its ability in controlling TGFβ/Smads pathway signalling activa-
tion.
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